Ticker Sage

Company file · UTHR

United Therapeutics

United Therapeutics' revenue rose 10.6% in FY2025, to $3.2B, and net income rose 11.7% to $1.3B

Revenue rose 10.6% to $3.2B in FY2025, from $2.9B in FY2024. Net income rose 11.7% to $1.3B. United States was the largest region, at 95% of revenue.

Key facts

United Therapeutics (Nasdaq: UTHR) closed fiscal 2025 on Dec 31, 2025 with revenue of $3.2B, up 10.6% from a year before; net income came to $1.3B, up 11.7%. Its newest quarterly report covers the three months to Sep 30, 2026: revenue of $832M, up 4.1% on the same stretch of the prior year, and net income of $259M. Broken down by region, United States led with 95% of fiscal 2025 revenue. Sources: 10-K for fiscal 2025 (filed Feb 25, 2026) and 10-Q for the quarter ended Sep 30, 2026 (filed Nov 4, 2026).

Revenue$3.2BFY2025 · +10.6% vs FY2024
Net income$1.3BFY2025 · +11.7% vs FY2024
Operating cash flow$1.6BFY2025 · +17.6% vs FY2024
Cash & equivalents$1.2Bat Sep 30, 2026 · −23.6% vs FY2025 end
Diluted shares48MFY2025 avg · −1.2% vs FY2024
Revenue and net income, three fiscal yearsBy fiscal year, $bn
RevenueNet income
Revenue and net income by fiscal yearRevenue FY2023: $2.3B2.3Net income FY2023: $985M0.98FY2023Revenue FY2024: $2.9B2.9Net income FY2024: $1.2B1.2FY2024Revenue FY2025: $3.2B3.2Net income FY2025: $1.3B1.3FY2025Data: Ticker Sage, from SEC EDGAR · tickersage.com

Source: 10-K FY2025, filed Feb 25, 2026

Quarterly revenue: fiscal 2026 vs a year earlierFiscal Q1–Q3, $bn (each quarter from that quarter's 10-Q)
FY2025FY2026
Quarterly revenue, fiscal 2026 vs 2025FY2025 Q1: $794M0.79FY2026 Q1: $782M0.78Q1FY2025 Q2: $799M0.80FY2026 Q2: $783M0.78Q2FY2025 Q3: $800M0.80FY2026 Q3: $832M0.83Q3Data: Ticker Sage, from SEC EDGAR · tickersage.com

Source: 10-Q filed May 6, 2026 · 10-Q filed Aug 5, 2026 · 10-Q filed Nov 4, 2026

How it makes money

FY2025 total by categoryUnited States: $3.0B (95%)Non-US: $146M (5%)$3.2BFY2025 totalData: Ticker Sage, from SEC EDGARtickersage.com

By region, FY2025

  • LineAmountSharevs FY2024
  • United States$3.0B95%+10.9%
  • Non-US$146M5%+5.8%

Source: 10-K FY2025, XBRL breakdown

By region in FY2025: United States (95%) and Non-US (5%), as shares of total revenue. Total revenue was $3.2B.

By region: three-year mixShare of the total each fiscal year
United StatesNon-US

Source: 10-K FY2025

Learn more: Revenue vs. net income · Gross, operating and net margin

What changed last quarter

How the quarter compared with a year earlier

Comparing Q3 2026 (Jul to Sep 2026) compared with Q3 2025 (Jul to Sep 2025)

Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.

Q3 2026Q3 2025

Company

Revenue
$832M Q3 2026
$800M Q3 2025
4.1% increase
Net income
$259M Q3 2026
$339M Q3 2025
23.6% decrease

Source: United Therapeutics 10-Q for the quarter ended Sep 30, 2026, filed Nov 4, 2026

By region

United States
$808M Q3 2026
$775M Q3 2025
4.3% increase
Non-US
$24M Q3 2026
$25M Q3 2025
2.8% decrease

Source: United Therapeutics 10-Q for the quarter ended Sep 30, 2026, filed Nov 4, 2026

  • Cash & equivalents $1.2B at Sep 30, 2026, vs $1.6B at FY2025 end.
  • Operating cash flow, first 9 months of fiscal 2026: $1.1B vs $1.2B a year earlier.

The bull case and the bear case

The bull case

  • Revenue rose 10.6% in FY2025 to $3.2B, from $2.9B a year earlier. 10-K, FY2025
  • Net income rose 11.7% in FY2025 to $1.3B, from $1.2B. 10-K, FY2025
  • Operating cash flow rose 17.6% in FY2025 to $1.6B. 10-K, FY2025
  • Diluted shares fell 1.2% in FY2025, so each share represents a larger slice of profit. 10-K, FY2025

The bear case

  • Net income in the quarter ended Sep 30, 2026 was $259M, down 23.6% on a year earlier. 10-Q, quarter ended Sep 30, 2026
  • The company's own risk factors are in Item 1A of its 10-K. Risks common in this industry include regulation; pricing and reimbursement; competition. 10-K, Item 1A

What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.

What the company does

United Therapeutics is in the biotechnology industry, part of the health care sector. The SEC files it under Pharmaceutical Preparations.

The full description of United Therapeutics' business is in Item 1 of its 10-K, linked below. This page shows its revenue by region.

Its fiscal year ends in December; the latest, FY2025, ended Dec 31, 2025.

Source: 10-K, Item 1 Business

Risks common in this industry

These are general risks for companies in the biotechnology industry. They are not a summary of United Therapeutics’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.

  1. RegulationApprovals, safety rules and government oversight shape what it can sell and how.
  2. Pricing and reimbursementPayers, insurers and governments influence what it can charge.
  3. CompetitionNew treatments, generics and rival products can take share.
  4. LitigationProduct liability and other legal claims can lead to costs.
  5. SupplyManufacturing and supplier problems can interrupt products.

Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)

Three years of key numbers

Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.

US$FY2023FY2024FY2025
Revenue$2.3B$2.9B$3.2B
Net income$985M$1.2B$1.3B
Operating cash flow$978M$1.3B$1.6B
Cash & equivalents (year end)$1.2B$1.7B$1.6B
Diluted shares50M48M48M
  • Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
  • Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
  • Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
  • Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
  • Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.

Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator

Explainers for this page

Guides to terms this file uses, with real numbers from filings.

About these numbers

    What we left out

    • Total debt: the company's filing data doesn't carry a consistent debt total for the years shown, so it isn't shown.

    Recent filings

    FormFiledPeriod
    10-QNov 4, 2026Sep 30, 2026
    10-QAug 5, 2026Jun 30, 2026
    10-QMay 6, 2026Mar 31, 2026
    DEF 14AApr 29, 2026Jun 26, 2026
    10-KFeb 25, 2026Dec 31, 2025

    What's in this filing

    The quotes below come from Item 1 (Business) of the Form 10-K United Therapeutics filed on Feb 25, 2026, its annual report for the fiscal year ended Dec 31, 2025.

    The latest quarterly report in the table above is the Form 10-Q filed Nov 4, 2026 for the quarter ended Sep 30, 2026.

    A 10-K has audited annual financial statements and the company's own description of its business and risks; a 10-Q has unaudited quarterly statements.

    Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs.

    Source: Form 10-K, Item 1 (Business), filed Feb 25, 2026

    Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.

    Source: Form 10-K, Item 1 (Business), filed Feb 25, 2026

    Short excerpts quoted from the filing. The full document is on SEC.gov.

    Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters

    Common questions about United Therapeutics

    How does United Therapeutics make money?

    Fiscal 2025 revenue: $3.2B. By region in FY2025: United States (95%) and Non-US (5%), as shares of total revenue. Total revenue was $3.2B. Source: 10-K for fiscal 2025, filed Feb 25, 2026.

    What was United Therapeutics's revenue in fiscal 2025?

    $3.2B, up 10.6% from fiscal 2024 ($2.9B). The year ended Dec 31, 2025; for fiscal 2023 the figure was $2.3B. Source: 10-K for fiscal 2025, filed Feb 25, 2026.

    Is United Therapeutics profitable?

    Net income was $1.3B in fiscal 2025 (up 11.7%; fiscal 2024 was $1.2B). That counts as a GAAP profit. The latest quarter, ended Sep 30, 2026: net income was $259M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2025, filed Feb 25, 2026.

    What did United Therapeutics report in its latest quarterly filing?

    For the three months to Sep 30, 2026: revenue $832M (up 4.1% from $800M) and net income $259M (down 23.6% from $339M). Source: 10-Q for the quarter ended Sep 30, 2026, filed Nov 4, 2026.

    What are the main risks United Therapeutics faces?

    United Therapeutics's own risk factors are in Item 1A of its 10-K for fiscal 2025, filed Feb 25, 2026. Risks that are common among companies in the biotechnology industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.

    Where do these United Therapeutics numbers come from?

    The 10-K filed Feb 25, 2026 (fiscal 2025) and the 10-Q filed Nov 4, 2026 (quarter ended Sep 30, 2026), as published in the SEC's XBRL data. Click any number to open the filing it came from. Methodology explains how fiscal years and missing numbers are handled.

    Tracked funds that report owning United Therapeutics

    From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.

    Disclosures

    Editor holdings in UTHR
    The editor holds no position in United Therapeutics (UTHR). As of Nov 11, 2026.
    Trading rule
    The editor does not buy or sell UTHR from 3 days before to 3 days after this page is published or substantively updated.
    Compensation
    Nobody paid for this page. No affiliate links on this page.
    Sources
    The company's SEC filings, linked next to each number or, for charts, in the source line under them.
    Last updated
    Nov 19, 2026

    General education, the same for every reader. Not a recommendation to buy, sell or hold UTHR, and it doesn't consider your situation.

    Compare with peers

    CompanyFiscal yearRevenueRevenue growthNet income
    United TherapeuticsUTHRFY2025$3.2B+10.6%$1.3B
    AbbVieABBVFY2025$61.2B+8.6%$4.2B
    AmgenAMGNFY2025$36.8B+10.0%$7.7B
    GileadGILDFY2025$29.4B+2.4%$8.5B
    Vertex PharmaceuticalsVRTXFY2025$12.0B+8.9%$4.0B

    Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.

    More company files

    New to filings? Learn has explainers built on real filings and Tools has calculators. Methodology & Disclosures covers where every number comes from.